keyword
MENU ▼
Read by QxMD icon Read
search

Lupus cohort

keyword
https://www.readbyqxmd.com/read/29448881/outcomes-of-multitarget-therapy-using-mycophenolate-mofetil-and-tacrolimus-for-refractory-or-relapsing-lupus-nephritis
#1
C-B Choi, S Won, S-C Bae
Objectives Outcomes of systemic lupus erythematosus (SLE) have significantly improved over the years. However, when there is major organ involvement, the outcomes can still be unfavorable. Outcomes of multitarget therapy using mycophenolate mofetil (MMF) and tacrolimus in patients with SLE who were refractory to standard therapy were assessed. Methods We retrospectively reviewed the Hanyang BAE lupus cohort to identify patients with biopsy-confirmed lupus nephritis (classes III, IV, or V) who failed to either achieve complete response with standard induction therapy or those who had a lupus flare after achieving a complete response with conventional induction therapy and subsequently were switched to multitarget combination therapy with MMF and tacrolimus...
January 1, 2018: Lupus
https://www.readbyqxmd.com/read/29447842/neutrophils-drive-type-i-interferon-production-and-autoantibodies-in-wiskott-aldrich-syndrome
#2
K E Cervantes-Luevano, N Caronni, M C Castiello, E Fontana, G Piperno, A Naseem, P Uva, M Bosticardo, G E Marcovecchio, L D Notarangelo, M P Cicalese, A Aiuti, A Villa, F Benvenuti
BACKGROUND: Wiskott-Aldrich syndrome (WAS) is a rare primary immunodeficiency caused by mutations in WASp, a key regulator of cytoskeletal dynamics in hematopoietic cells. A high proportion of patients develop autoimmunity due to a breakdown in T and B cell tolerance. Moreover, excessive production of type-I interferon by plasmacytoid DCs contribute to autoimmune signs, however, the factors that triggers excessive innate activation have not been defined. OBJECTIVE: Neutrophils extracellular traps (NETs) emerged as major initiating factors in diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)...
February 12, 2018: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/29440621/urinary-levels-of-sirtuin-1-associated-with-disease-activity-in-lupus-nephritis
#3
Dolores Olivares, Javier Perez-Hernandez, Maria J Forner, Cristina Pérez-Soriano, Maria C Tormos, Guillermo T Sáez, Felipe J Chaves, Josep Redón, Raquel Cortés
Identifying new markers of disease flares in lupus nephritis (LN) that facilitate patient stratification and prognosis is important. Therefore, the aim of this study was to analyze whether urinary SIRT1 expression was altered in LN and whether SIRT1 values in urine could be valuable biomarker of disease activity. In a cohort study, urinary pellets from 40 patients diagnosed with systemic lupus erythematosus (SLE) were analyzed. Clinical measures of lupus activity were assessed. The expression of SIRT1 was quantified by quantitative PCR (qRT-PCR) and immunoblot, then compared between patients with active lupus nephritis, in remission and healthy controls...
February 12, 2018: Clinical Science (1979-)
https://www.readbyqxmd.com/read/29439873/prevalence-and-factors-associated-with-fatigue-in-female-patients-with-systemic-lupus-erythematosus
#4
Irene Carrión-Barberà, Tarek Carlos Salman-Monte, Sonia Castell, Francisco Castro, Fabiola Ojeda, Jordi Carbonell
OBJECTIVE: To determine the prevalence of fatigue in our cohort as well as the factors to which it is associated, its relationship with demographic variables, vitamin D levels, treatment, systemic lupus erythematosus (SLE) symptoms and disease activity. METHODS: A cross-sectional study was carried out including 102 consecutive female patients with SLE (American College of Rheumatology 1997 criteria) who attended the Parc de Salut Mar between January 2012 and May 2014...
February 10, 2018: Medicina Clínica
https://www.readbyqxmd.com/read/29431056/characteristics-of-systemic-lupus-erythematosus-in-a-sample-of-the-egyptian-population-a-retrospective-cohort-of-1109-patients-from-a-single-center
#5
K T El Hadidi, B M Medhat, N M Abdel Baki, H Abdel Kafy, W Abdelrahaman, A Y Yousri, D H Attia, M Eissa, D El Dessouki, I Elgazzar, F T Elgengehy, N El Ghobashy, H El Hadary, G El Mardenly, H El Naggar, A M El Nahas, R M El Refai, H Allah El Rwiny, R M Elsman, M Galal, S Ghoniem, L A Maged, S M Sally, H Naji, S Saad, M Shaaban, M Sharaf, N Sobhy, R M Soliman, T S El Hadidi
Introduction Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease that can vary among different ethnic and racial groups. Objective The objective of this paper is to study the prevalence of various manifestations of SLE in a sample of the Egyptian population. Patients and methods Information in this study was derived from the medical records of SLE patients who sought medical advice at a private clinic in Cairo from January 1980 to June 2016. Results This study included 1109 SLE patients, of whom 114 (10...
January 1, 2018: Lupus
https://www.readbyqxmd.com/read/29427555/therapeutic-adherence-in-patients-with-systemic-lupus-erythematosus-a-cross-sectional-study
#6
Lucia Mazur-Nicorici, Victoria Sadovici-Bobeica, Maria Garabajiu, Minodora Mazur
INTRODUCTION: The aim of the research was the study of the adherence to treatment in patients with systemic lupus erythematosus. METHODS: Cross-sectional study including 132 consecutive patients with systemic lupus erythematosus (SLICC, 2012 classification criteria). We collected clinical and socio-demographic data, socio-economic status; we assessed SLEDAI-2k disease activity, and estimated the adherence to treatment by Morisky questionnaire. RESULTS: Our results demonstrated that low adherence to treatment in patients with systemic lupus erythematosus was in only 11...
February 6, 2018: Romanian Journal of Internal Medicine, Revue Roumaine de Médecine Interne
https://www.readbyqxmd.com/read/29423203/causes-and-predictors-of-mortality-in-biopsy-proven-lupus-nephritis-the-sarawak-experience
#7
Cheng Lay Teh, Vui Eng Phui, Guo Ruey Ling, Lui-Sian Ngu, Sharifah Aishah Wan, Clare Hui-Hong Tan
Background: Lupus nephritis (LN) is a serious manifestation of systemic lupus erythematosus that can be fatal if left untreated. The causes and prognostic predictors of mortality in LN have been well studied in developed countries but evidence is lacking for developing countries. The objective of this study was to investigate the causes and predictors of mortality in a cohort of Malaysian patients with biopsy-proven LN. Methods: We retrospectively studied all patients with biopsy-proven LN treated in Sarawak General Hospital during the period of 2000-15...
February 2018: Clinical Kidney Journal
https://www.readbyqxmd.com/read/29419473/feasibility-validity-and-reliability-of-the-10-item-patient-reported-outcomes-measurement-information-system-global-health-short-form-in-outpatients-with-systemic-lupus-erythematosus
#8
Shanthini Kasturi, Jackie Szymonifka, Jayme C Burket, Jessica R Berman, Kyriakos A Kirou, Alana B Levine, Lisa R Sammaritano, Lisa A Mandl
OBJECTIVE: To assess the feasibility, validity, and reliability of the Patient Reported Outcomes Measurement Information System Global Health Short Form (PROMIS10) in outpatients with systemic lupus erythematosus (SLE). METHODS: SLE outpatients completed PROMIS10, Medical Outcomes Study Short Form-36 (SF-36), LupusQoL-US, and selected PROMIS computerized adaptive tests (CAT) at routine visits at an SLE Center of Excellence. Construct validity was evaluated by correlating PROMIS10 physical and mental health scores with PROMIS CAT, legacy instruments, and physician-derived measures of disease activity and damage...
February 1, 2018: Journal of Rheumatology
https://www.readbyqxmd.com/read/29410944/clinical-outcomes-observed-among-biopsy-proven-lupus-nephritis-patients-treated-with-mycophenolate-mofetil-as-first-line-therapy
#9
Homa Timlin, Laurence Magder, Michelle Petri
Background and objective The rate of end-stage renal disease from lupus nephritis has not declined, in spite of recent advances in therapeutics, such as mycophenolate mofetil (MMF). To provide insight into rates of the clinical outcomes in current practice after biopsy-proven lupus nephritis, we used a prospective cohort of the patients with newly diagnosed lupus nephritis, treated with MMF and observed their outcomes. Method Twenty systemic lupus erythematosus (SLE) patients who began mycophenolate mofetil shortly after a biopsy-confirmed diagnosis of lupus nephritis were included in the analysis...
December 4, 2017: Curēus
https://www.readbyqxmd.com/read/29406037/research-ethics-in-behavioral-interventions-among-special-populations-lessons-from-the-peer-approaches-to-lupus-self-management-study
#10
EDITORIAL
Trevor D Faith, Leonard Egede, Edith M Williams
BACKGROUND: Research involving a homogenous cohort of participants belonging to a special population must make considerations to recruit and protect the subjects. This study analyses the ethical considerations made in the peer approaches to lupus self-management project which pilot tested a peer mentoring intervention for African American women with systemic lupus erythematosus. METHODS: Considerations made at the outset of the project are described and their justifications and reasoning are given...
February 2018: American Journal of the Medical Sciences
https://www.readbyqxmd.com/read/29396242/lupus-nephritis-with-preserved-kidney-function-associated-with-poorer-cardiovascular-risk-control-a-call-for-more-awareness
#11
J A Todolí-Parra, Y Tung-Chen, L Micó, J Gutiérrez, J Hernández-Jaras, J L Ruiz-Cerda
BACKGROUND: Despite the improvement in the prognosis of lupus nephritis (LN), the cardiovascular morbimortality remains high. The early recognition and remission of flares, while trying to avoid the metabolic adverse effects of medication, must be mandatory. AIM: The aim of our study was to assess the cardiovascular (CV) risk profile in a cohort of lupus patients with preserved kidney function after a nephritis episode, compared to patients without a nephritis flare...
January 27, 2018: Hipertensión y Riesgo Vascular
https://www.readbyqxmd.com/read/29395351/end-stage-renal-disease-and-mortality-outcomes-across-different-glomerulonephropathies-in-a-large-diverse-us-population
#12
John J Sim, Simran K Bhandari, Michael Batech, Aviv Hever, Teresa N Harrison, Yu-Hsiang Shu, Dean A Kujubu, Tracy Y Jonelis, Michael H Kanter, Steven J Jacobsen
OBJECTIVE: To compare renal function decline, incident end-stage renal disease (ESRD), and mortality among patients with 5 common glomerular diseases in a large diverse population. PATIENTS AND METHODS: A retrospective cohort study (between January 1, 2000, and December 31, 2011) of patients with glomerulonephropathy using the electronic health record of an integrated health system was performed. Estimated glomerular filtration rate (eGFR) change, incident ESRD, and mortality were compared among patients with biopsy-proven focal segmental glomerulosclerosis (FSGS), membranous glomerulonephritis (MN), minimal change disease (MCD), immunoglobulin A nephropathy (IgAN), and lupus nephritis (LN)...
January 9, 2018: Mayo Clinic Proceedings
https://www.readbyqxmd.com/read/29394927/quantification-of-cancer-risk-in-glomerulonephritis
#13
James Goya Heaf, Alastair Hansen, Gunnar Hellmund Laier
BACKGROUND: The association of increased cancer risk with glomerulonephritis (GN) is well known, but controversy exists concerning which types of GN are involved, and the size of the association. A national registry survey was performed to assess the size of this association, and the temporal relationship of cancer diagnosis to GN diagnosis. METHODS: All patients with biopsy-proven GN between 1985 and 2015 in Denmark were extracted from The Danish Renal Biopsy Registry and the National Pathology Data Bank...
February 2, 2018: BMC Nephrology
https://www.readbyqxmd.com/read/29371048/serum-microrna-screening-and-functional-studies-reveal-mir-483-5p-as-a-potential-driver-of-fibrosis-in-systemic-sclerosis
#14
Eleni Chouri, Nila H Servaas, Cornelis P J Bekker, Alsya J Affandi, Marta Cossu, Maarten R Hillen, Chiara Angiolilli, Jorre S Mertens, Lucas L van den Hoogen, Sandra Silva-Cardoso, Maarten van der Kroef, Nadia Vazirpanah, Catharina G K Wichers, Tiago Carvalheiro, Sofie L M Blokland, Barbara Giovannone, Laura Porretti, Wioleta Marut, Barbara Vigone, Joel A G van Roon, Lorenzo Beretta, Marzia Rossato, Timothy R D J Radstake
OBJECTIVE: MicroRNAs (miRNAs) are regulatory molecules, which have been addressed as potential biomarkers and therapeutic targets in rheumatic diseases. Here, we investigated the miRNA signature in the serum of systemic sclerosis (SSc) patients and we further assessed their expression in early stages of the disease. METHODS: The levels of 758 miRNAs were evaluated in the serum of 26 SSc patients as compared to 9 healthy controls by using an Openarray platform. Three miRNAs were examined in an additional cohort of 107 SSc patients and 24 healthy donors by single qPCR...
January 19, 2018: Journal of Autoimmunity
https://www.readbyqxmd.com/read/29364894/serum-calcification-propensity-is-independently-associated-with-disease-activity-in-systemic-lupus-erythematosus
#15
Suzan Dahdal, Vasilios Devetzis, George Chalikias, Dimitrios Tziakas, Carlo Chizzolini, Camillo Ribi, Marten Trendelenburg, Ute Eisenberger, Thomas Hauser, Andreas Pasch, Uyen Huynh-Do, Spyridon Arampatzis
BACKGROUND: Systemic lupus erythematosus (SLE) is associated with severe cardiovascular complications. The T50 score is a novel functional blood test quantifying calcification propensity in serum. High calcification propensity (or low T50) is a strong and independent determinant of all-cause mortality in various patient populations. METHODS: A total of 168 patients with ≥ 4 American College of Rheumatology (ACR) diagnostic criteria from the Swiss Systemic lupus erythematosus Cohort Study (SSCS) were included in this analysis...
2018: PloS One
https://www.readbyqxmd.com/read/29363290/cancer-immunotherapy-in-patients-with-preexisting-rheumatologic-disease-the-mayo-clinic-experience
#16
Michael D Richter, Olga Pinkston, Lisa A Kottschade, Heidi D Finnes, Svetomir N Markovic, Uma Thanarajasingam
OBJECTIVES: To determine the risk of rheumatologic disease flare and adverse effects in patients with preexisting rheumatologic disease receiving checkpoint inhibitor therapy. METHODS: A retrospective medical record review was performed to identify all patients who received checkpoint inhibitor therapy at Mayo Clinic, Rochester between 2011 and 2016 (approximately 5,200 patients). Those with preexisting rheumatologic disease were identified using specific diagnostic codes...
January 24, 2018: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/29361147/glucocorticoid-use-and-factors-associated-with-variability-in-this-use-in-the-systemic-lupus-international-collaborating-clinics-inception-cohort
#17
Jayne Little, Ben Parker, Mark Lunt, John G Hanly, Murray B Urowitz, Ann E Clarke, Juanita Romero-Diaz, Caroline Gordon, Sang-Cheol Bae, Sasha Bernatsky, Daniel J Wallace, Joan T Merrill, Jill Buyon, David A Isenberg, Anisur Rahman, Ellen M Ginzler, Michelle Petri, Mary Anne Dooley, Paul Fortin, Dafna D Gladman, Kristjan Steinsson, Rosalind Ramsey-Goldman, Munther A Khamashta, Cynthia Aranow, Meggan Mackay, Graciela S Alarcón, Susan Manzi, Ola Nived, Andreas Jönsen, Asad A Zoma, Ronald F van Vollenhoven, Manuel Ramos-Casals, Guillermo Ruiz-Irastorza, Sung Sam Lim, Kenneth C Kalunian, Murat Inanc, Diane L Kamen, Christine A Peschken, Soren Jacobsen, Anca Askanase, Jorge Sanchez-Guerrero, Ian N Bruce
Objectives: To describe glucocorticoid (GC) use in the SLICC inception cohort and to explore factors associated with GC use. In particular we aimed to assess temporal trends in GC use and to what extent physician-related factors may influence use. Methods: Patients were recruited within 15 months of diagnosis of SLE from 33 centres between 1999 and 2011 and continue to be reviewed annually. Descriptive statistics were used to detail oral and parenteral GC use. Cross sectional and longitudinal analyses were performed to explore factors associated with GC use at enrolment and over time...
January 18, 2018: Rheumatology
https://www.readbyqxmd.com/read/29356781/clinical-characteristics-and-associated-systemic-diseases-in-patients-with-esophageal-absent-contractility-a-clinical-algorithm
#18
Sobia Laique, Tavankit Singh, David Dornblaser, Abhishek Gadre, Vikram Rangan, Ronnie Fass, Donald Kirby, Soumya Chatterjee, Scott Gabbard
GOALS: This study was carried out to assess the clinical characteristics and associated systemic diseases seen in patients diagnosed with absent contractility as per the Chicago Classification version 3.0, allowing us to propose a diagnostic algorithm for their etiologic testing. BACKGROUND: The Chicago Classification version 3.0 has redefined major and minor esophageal motility disorders using high-resolution esophageal manometry. There is a dearth of publications based on research on absent contractility, which historically has been associated with myopathic processes such as systemic sclerosis (SSc)...
January 19, 2018: Journal of Clinical Gastroenterology
https://www.readbyqxmd.com/read/29342508/features-treatment-and-outcomes-of-macrophage-activation-syndrome-in-childhood-onset-systemic-lupus-erythematosus
#19
R Ezequiel Borgia, Maya Gerstein, Deborah M Levy, Earl D Silverman, Linda T Hiraki
OBJECTIVE: To describe the features and treatment of macrophage activation syndrome (MAS) in a childhood-onset systemic lupus erythematosus (cSLE) single centre cohort, and compare the cSLE manifestations and outcomes between those with and without MAS. METHODS: We included all cSLE patients followed at SickKids Hospital from 2002-12, and identified those also diagnosed with MAS. Demographic, clinical and laboratory features of MAS and SLE, medication use, hospital and PICU admissions as well as damage indices and mortality were extracted from the Lupus database...
January 17, 2018: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/29338588/epstein-barr-virus-infection-and-type-i-interferon-signature-in-patients-with-systemic-lupus-erythematosus
#20
L Han, Y Zhang, Q Wang, M Xin, K Yang, K Lei, M Sun
Epstein-Barr (EB) virus infection has long been speculated to evoke systemic lupus erythematosus (SLE). Since a virus infection can induce interferon (IFN) system activation, we aimed to discover the relationship between the two in the progression of SLE in a Chinese inpatient cohort. Methods Peripheral blood mononuclear cells and sera were isolated from 116 SLE patients and 76 healthy controls. Antibodies against EBV-VCA (IgM and IgG) and EBNA (IgG) along with IFNα in patient sera were detected with enzyme-linked immunosorbent assays...
January 1, 2018: Lupus
keyword
keyword
30859
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"